Use of real-world evidence for oncology clinical decision making in emerging economies

被引:12
|
作者
Petracci, Fernando [1 ]
Ghai, Chirag [2 ]
Pangilinan, Andrew [2 ]
Suarez, Luis Alberto [3 ]
Uehara, Roberto [4 ]
Ghosn, Marwan [5 ,6 ]
机构
[1] Inst Alexander Fleming, Breast Canc Dept, Ave Cramer 1180, RA-1426 Buenos Aires, Argentina
[2] Real World Evidence Strategy & Solut, IQVIA, New York, NY 10282 USA
[3] Pfizer Inc, B1607EEV, Buenos Aires, DF, Argentina
[4] Pfizer Inc, New York, NY 10017 USA
[5] France Univ Hosp, Hotel Dieu, Hematol & Oncol Dept, Beirut, Lebanon
[6] St Joseph Univ, Beirut, Lebanon
关键词
Asia-Pacific; effectiveness; electronic database; health policy; Latin America; Middle East; randomized clinical trials; real-world data; real-world evidence; safety; RENAL-CELL CARCINOMA; CANCER-PATIENTS; SUNITINIB; PROGRESSION; RESISTANCE; EFFICACY; THERAPY; TRIALS; SAFETY; HEALTH;
D O I
10.2217/fon-2021-0425
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Lay abstract Traditionally, randomized clinical trials have been used to provide insights on new medical therapies and continue to remain the gold standard for approval. The-increasing availability of patient level data in the real-world, it is now possible to generate evidence regarding the usage and potential benefits or risks of a medical therapy derived from analysis of real-world data. This evidence is collectively referred to real-world evidence (RWE). randomized clinical trials and RWE are complementary and the area of Oncology especially benefits from RWE to guide clinical decision making across the patient journey. Key benefits include cancer screening and diagnosis, optimal treatment choices (including personalized medicine) and disease management such as dosing and treatment of side effects. In recent times, RWE generation in oncology has been prolific in the USA and western Europe. With expansive biopharmaceutical investments into infrastructure harnessing patient-level data and greater local regulatory guidance, oncology patients in emerging economies may now also have the opportunity to benefit from clinical decision making informed by RWE. Real-world evidence (RWE) can provide insights into patient profiles, disease detection, treatment choice, dosing strategies, treatment sequencing, adverse event management and financial toxicity associated with oncology treatment. However, the full potential of RWE is untapped in emerging economies due to structural and behavioral factors. Structural barriers include lack of regulatory engagement, real-world data availability, quality and integrity. Behavioral barriers include entrenched healthcare professional behaviors that impede rapid RWE understanding and adoption. These barriers can be addressed with close collaboration of healthcare stakeholders; of whom, regulators need to be at the forefront given their ability to facilitate use of RWE in healthcare policy and legislation.
引用
收藏
页码:2951 / 2960
页数:10
相关论文
共 50 条
  • [21] PERCEPTIONS OF CLINICIANS ON THE USE OF REAL-WORLD EVIDENCE IN ONCOLOGY: AN EORTC SURVEY
    Saesen, R.
    Marinus, A.
    Lacombe, D.
    Huys, I
    VALUE IN HEALTH, 2022, 25 (01) : S252 - S253
  • [22] INTEGRATION OF CLAIMS AND CLINICAL DATA TO ENABLE REAL-WORLD EVIDENCE IN ONCOLOGY
    Nguyen, C.
    Zheng, H.
    Grabner, M.
    Vojjala, S. K.
    Barron, J.
    Sweet, B.
    Hill, N.
    VALUE IN HEALTH, 2023, 26 (06) : S370 - S371
  • [23] The role of real-world evidence in clinical care: A survey of oncology leaders
    Stahl, Melissa
    Winzeler, Alissa M.
    Zaman, Ali
    Shelby, Nicole
    Chen, James Lin
    Clutz, Bryan
    Ghosh, Aradhana
    Hirsch, Jonathan
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [24] REAL-WORLD EVIDENCE ON THE RISE: EVALUATING THE USE OF REAL-WORLD EVIDENCE IN ICER ASSESSMENTS OF COMPARATIVE CLINICAL EFFECTIVENESS
    Drane, E.
    Upton, E.
    Morten, P.
    Walker, E.
    VALUE IN HEALTH, 2019, 22 : S316 - S316
  • [25] Real-World Evidence for Regulatory Decision-Making: Guidance From Around the World
    Burns, Leah
    Le Roux, Nadege
    Kalesnik-Orszulak, Robert
    Christian, Jennifer
    Hukkelhoven, Mathias
    Rockhold, Frank
    O'Donnell, John
    CLINICAL THERAPEUTICS, 2022, 44 (03) : 420 - 437
  • [26] The Current Landscape and Emerging Applications for Real-World Data in Diagnostics and Clinical Decision Support and its Impact on Regulatory Decision Making
    Andre, Elodie Baumfeld
    Carrington, Nate
    Siami, Flora S.
    Hiatt, Jo Carol
    McWilliams, Carly
    Hiller, Carolyn
    Surinach, Andy
    Zamorano, Alejandro
    Pashos, Chris L.
    Schulz, Wade L.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2022, 112 (06) : 1172 - 1182
  • [27] Real-World Evidence in Oncology: Opportunities and Limitations
    Di Maio, Massimo
    Perrone, Francesco
    Conte, Pierfranco
    ONCOLOGIST, 2020, 25 (05): : E746 - E752
  • [28] Precision Oncology Program - Integration of Real World Data in Clinical Decision Making
    Boos, L. A.
    Gut, G.
    Miglino, N.
    Fabregas-Ibanez, L.
    Schmid, M. P.
    Zoche, M.
    Aguilera, D.
    Arnold, F.
    Dorig, C.
    Fruchtenicht, C.
    Rizzo, S.
    Huntley, M.
    Bosshard, K.
    Bodmer, M.
    Glinz, D.
    Kaczmarek, L.
    Chitale, N.
    Lozano, O.
    Nowak, M.
    Gosztonyi, B.
    Rahmani-Khajouei, S.
    Rahimzadeh, P.
    Wicki, A.
    SWISS MEDICAL WEEKLY, 2023, 153 : 53S - 53S
  • [30] REAL-WORLD EVIDENCE (RWE) OPPORTUNITIES TO ENHANCE LOCAL DECISION-MAKING IN ONCOLOGY FOR EMERGING MARKETS: A MULTI-REGIONAL ONCOLOGIST & PAYER COMMITTEE PERSPECTIVE
    Guarin, A.
    Bazarbashi, S.
    Chiu, A.
    Hamad, A.
    Sc, Lee
    Petracci, F.
    Stefani, S.
    Wong, C.
    Ghai, C.
    VALUE IN HEALTH, 2023, 26 (06) : S371 - S371